<DOC>
	<DOCNO>NCT00494780</DOCNO>
	<brief_summary>To investigate efficacy two dose regimen ofatumumab combination CHOP ( cyclophosphamide , doxorubicin , vincristine , prednisolone ) previously untreated patient Follicular Lymphoma ( FL )</brief_summary>
	<brief_title>Ofatumumab ( Humax-CD20 ) With CHOP ( Cyclophosphamide , Doxorubicin , Vincristine , Predisolone ) Follicular Lymphoma ( FL ) Patients</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>Patient Follicular Lymphoma ( FL ) Confirmed diagnosis Follicular lymphoma 18 year Verbal write information study No previous treatment Follicular Lymphoma Clinical suspicion Follicular Lymphoma transform aggressive lymphoma Several disease malignancy etc . Screening laboratory value Current participation interventional clinical study Breast feed woman pregnant woman Women childbearing potential willing use adequate contraception</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>CHOP ( cyclophosphamide , doxorubicin , vincristine , prednisolone )</keyword>
	<keyword>ofatumumab</keyword>
</DOC>